Novel pyroptosis-immune-related lncRNA signature exhibits a distinct immune cell infiltration landscape in breast cancer
IntroductionThis study investigated pyroptosis- and immunity-related long non-coding RNAs (lncRNAs) to identify promising therapeutic targets for breast cancer (BC), and constructed lncRNA signatures to determine the prognosis and immunotherapy responses of BC patients.MethodsPearson’s correlation c...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1522327/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832592417827586048 |
|---|---|
| author | Dedi Kong Dedi Kong Hongju Cheng Meihong Wang |
| author_facet | Dedi Kong Dedi Kong Hongju Cheng Meihong Wang |
| author_sort | Dedi Kong |
| collection | DOAJ |
| description | IntroductionThis study investigated pyroptosis- and immunity-related long non-coding RNAs (lncRNAs) to identify promising therapeutic targets for breast cancer (BC), and constructed lncRNA signatures to determine the prognosis and immunotherapy responses of BC patients.MethodsPearson’s correlation coefficient was used to identify pyroptosis- and immune-related differentially expressed lncRNAs (DE-pyrolncRNAs and DE-ImmlncRNAs, respectively). The Cancer Genome Atlas dataset was allocated to training and testing subsets. Prognostic lncRNA signatures were derived based on the training subset using univariate Cox regression analysis and Least Absolute Shrinkage and Selection Operator methods. Stepwise Cox regression was used to refine these signatures and to select the optimal lncRNA signature. The median risk score of the training subset was applied as a threshold to divide patients into high-risk (HR) and low-risk (LR) groups. The Wilcoxon test was used to reveal differences in immune scores, cell types, functions, and checkpoint genes between these groups. Single-cell sequencing data from GSE176078 were used to validate the immune cell infiltration landscape of the identified lncRNA signatures.ResultsWe identified a six-lncRNA pyroptosis-immune signature comprising MAPT.AS1, CTA.384, D8.34, RP11.561, I11.3, HID1.AS1, AC097713.3, and USP2.AS1. Patients in the HR group demonstrated inferior prognoses in the training, testing, and full datasets (P=3.622e-07, P=3.736e-03, and P=1.151e-08, respectively). Immune scores were significantly enhanced in the LR group, whereas tumor purity was elevated in the HR group. Fifty-eight immune scores showed significant differences between the groups (P<0.05). Immune function (APC coinhibition, CCR, and checkpoints) more significantly impaired in the HR group. Expression levels of 38 immune checkpoint genes, including KIR2DS4, KIR3DL2, CD40LG, KIR3DL1, and PDCD1, were significantly higher in the LR group. Conversely, the TDO2, PVR, and CD276 levels were elevated in the HR group. Single-cell sequencing data from GSE176078 showed sparse T cell, B cell, myeloid, and plasmablast clusters in the HR group, whereas the LR group displayed significant clustering of B cells, myeloids, and plasmablasts.ConclusionThe six-lncRNA pyroptosis-immune signature effectively predicted BC prognosis and highlighted distinct immune cell infiltration patterns. This holds promise for evaluating immunotherapy responses and guiding therapeutic target identification in BC. |
| format | Article |
| id | doaj-art-7adff7c72fa14d0690760a58f137de0e |
| institution | Kabale University |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-7adff7c72fa14d0690760a58f137de0e2025-01-21T08:37:05ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-01-011510.3389/fimmu.2024.15223271522327Novel pyroptosis-immune-related lncRNA signature exhibits a distinct immune cell infiltration landscape in breast cancerDedi Kong0Dedi Kong1Hongju Cheng2Meihong Wang3Shandong Qianfoshan Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, ChinaBreast and Thyroid Surgery, Jining No 1 People’s Hospital, Jining, Shandong, ChinaPhysiology Teaching and Research Office, Jining Medical College, Jining, Shandong, ChinaHematology Department, Jining No 1 People’s Hospital, Jining, Shandong, ChinaIntroductionThis study investigated pyroptosis- and immunity-related long non-coding RNAs (lncRNAs) to identify promising therapeutic targets for breast cancer (BC), and constructed lncRNA signatures to determine the prognosis and immunotherapy responses of BC patients.MethodsPearson’s correlation coefficient was used to identify pyroptosis- and immune-related differentially expressed lncRNAs (DE-pyrolncRNAs and DE-ImmlncRNAs, respectively). The Cancer Genome Atlas dataset was allocated to training and testing subsets. Prognostic lncRNA signatures were derived based on the training subset using univariate Cox regression analysis and Least Absolute Shrinkage and Selection Operator methods. Stepwise Cox regression was used to refine these signatures and to select the optimal lncRNA signature. The median risk score of the training subset was applied as a threshold to divide patients into high-risk (HR) and low-risk (LR) groups. The Wilcoxon test was used to reveal differences in immune scores, cell types, functions, and checkpoint genes between these groups. Single-cell sequencing data from GSE176078 were used to validate the immune cell infiltration landscape of the identified lncRNA signatures.ResultsWe identified a six-lncRNA pyroptosis-immune signature comprising MAPT.AS1, CTA.384, D8.34, RP11.561, I11.3, HID1.AS1, AC097713.3, and USP2.AS1. Patients in the HR group demonstrated inferior prognoses in the training, testing, and full datasets (P=3.622e-07, P=3.736e-03, and P=1.151e-08, respectively). Immune scores were significantly enhanced in the LR group, whereas tumor purity was elevated in the HR group. Fifty-eight immune scores showed significant differences between the groups (P<0.05). Immune function (APC coinhibition, CCR, and checkpoints) more significantly impaired in the HR group. Expression levels of 38 immune checkpoint genes, including KIR2DS4, KIR3DL2, CD40LG, KIR3DL1, and PDCD1, were significantly higher in the LR group. Conversely, the TDO2, PVR, and CD276 levels were elevated in the HR group. Single-cell sequencing data from GSE176078 showed sparse T cell, B cell, myeloid, and plasmablast clusters in the HR group, whereas the LR group displayed significant clustering of B cells, myeloids, and plasmablasts.ConclusionThe six-lncRNA pyroptosis-immune signature effectively predicted BC prognosis and highlighted distinct immune cell infiltration patterns. This holds promise for evaluating immunotherapy responses and guiding therapeutic target identification in BC.https://www.frontiersin.org/articles/10.3389/fimmu.2024.1522327/fullpyroptosisimmune infiltrationlncRNAbreast cancerprognosis |
| spellingShingle | Dedi Kong Dedi Kong Hongju Cheng Meihong Wang Novel pyroptosis-immune-related lncRNA signature exhibits a distinct immune cell infiltration landscape in breast cancer Frontiers in Immunology pyroptosis immune infiltration lncRNA breast cancer prognosis |
| title | Novel pyroptosis-immune-related lncRNA signature exhibits a distinct immune cell infiltration landscape in breast cancer |
| title_full | Novel pyroptosis-immune-related lncRNA signature exhibits a distinct immune cell infiltration landscape in breast cancer |
| title_fullStr | Novel pyroptosis-immune-related lncRNA signature exhibits a distinct immune cell infiltration landscape in breast cancer |
| title_full_unstemmed | Novel pyroptosis-immune-related lncRNA signature exhibits a distinct immune cell infiltration landscape in breast cancer |
| title_short | Novel pyroptosis-immune-related lncRNA signature exhibits a distinct immune cell infiltration landscape in breast cancer |
| title_sort | novel pyroptosis immune related lncrna signature exhibits a distinct immune cell infiltration landscape in breast cancer |
| topic | pyroptosis immune infiltration lncRNA breast cancer prognosis |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1522327/full |
| work_keys_str_mv | AT dedikong novelpyroptosisimmunerelatedlncrnasignatureexhibitsadistinctimmunecellinfiltrationlandscapeinbreastcancer AT dedikong novelpyroptosisimmunerelatedlncrnasignatureexhibitsadistinctimmunecellinfiltrationlandscapeinbreastcancer AT hongjucheng novelpyroptosisimmunerelatedlncrnasignatureexhibitsadistinctimmunecellinfiltrationlandscapeinbreastcancer AT meihongwang novelpyroptosisimmunerelatedlncrnasignatureexhibitsadistinctimmunecellinfiltrationlandscapeinbreastcancer |